Cytokines in the treatment of hematological disorders: Recent progress and perspectives

Archivum Immunologiae et Therapiae Experimentalis

Volumn 44, Issue 1, 1996, Pages 5-9

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

blood diseases; clinical applications of cytokines; hematopoietic growth factors; interferon ; interferon

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; BETA INTERFERON; CYTOKINE; ERYTHROPOIETIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON BETA SERINE; INTERLEUKIN 2; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HUMAN; LEUKEMIA; NEUTROPENIA; SHORT SURVEY;

COLONY-STIMULATING FACTORS; CYTOKINES; DRUG THERAPY; HEMATOLOGIC DISEASES; HUMANS; INTERFERONS; INTERLEUKINS; RECOMBINANT PROTEINS;

EID: 0029886973     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (33)

1. BALCERSKA A., BOHDAN Z_, DROZ̀YŃSKA E., KOZIELSKA E., SZARSZEWSKI A and GEORGIADES J A. (1993). Evaluation of the efficacy of natural human Interferon alpha lozenges in the clinical course of childhood neoplasia and in chronic hepatitis B virus infection in patients who were successfully treated for pediatric malignancies. Arch. Immunol. Ther. Exp., 41, 222-227.
2. BRENNER M. K. (1994): Haematological applications of interleukin-2 and other immunostimulatory cytokines. Baillieres Clin. Haematol., 7, 115-133.
3. BRONCHUD M. (1993): Can hemopoietic growth factors be used to improve the success of cytotoxic chemotherapy. Anticancer Drugs, 4, 127-132.
4. DAINIAK N., GNIGON M., BROXMEYER H. G., LEMOINE F. and NAJMAN A. (1994): Meeting on negative hematopopoietic cell growth and dillerentation. Exp. Haematol., 22, 399-405
5. DE SAUVAGE F. J., HASS P. E., SPENCER S. D., MALLOY B. E., GURNEY A. L. SPENCER S. A., DARBONNE W. C., KENZEI W. J., WONG S. C., KUANG W. J., OLES K. J., HULTGREN B., SOLBERG L A. JR. and GOEDDEL D. V. (1994): Stimulation of megakaryo-cytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature, 369, 533-538.
6. GÓRA-TYBOR J., WARZOCHA K. and ROBAK T. (1995): The influence of 2-chloro-deoxyadenosine (2-CdA) in combination with tumor necrosis factor α (TNF-α) or its mutein on murine leukemias L1210 and P388. Mediators Inflamm, 4, 205-208.
7. HANSEN P. B., HIPPE E., HELLSTROM-LINDBERU E. and RALFKIER E. (1993): Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin may improve anemia in selected patients with myelodysplasia. Am. J. Hematol., 44, 229-236
8. HEHLMAN R., HEIMPEL H., HASFORD J., KOLB H. J., PRALLE H., HOSSFELD D. K., QUEISSER W., LOFFLER H., HOCHHAUS A., HEINZE B. and GEORGII A. (1994): Randomized comparison of Interferon alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood, 84, 4064-4077.
9. HESLOP H. E. (1994): Cytokine gene transfer in the therapy of malignancy. Baillieres Clin. Haematol., 7, 135-151.
10. INGLOT A. D. (1994): Interferon-γ (IFN-γ). Miejsce w rodzinie cytokin - aktywność, zastosowanie kliniczne. Pamietnik Sympozjum Terapia Interferonem-γ -Nowy Kierunek w Terapii". Wyd. Centrum Zdrowia Dziccka i Boehringer Ingelheim., 46-53.
11. KLINGEMANN H. G and PHILIPS G. L. (1995): Is there a place for immunotherapy with interleukin 2 to prevent relapse after autologous stem cell transplantation for acute leukemia. Leuk. Lymphoma, 16, 397-405.
12. KOJINA S. and MATSUYAMA T. (1994): Stimulation of granulopoiesis by high-dose recombinant human granulocyte colony - stimulating factor in children with aplastic anemia and very severe neutropenia. Blood, 83, 1474-1478.
13. LORD B. J., DEXTER T. M., CLEMENTS J. M., HUNTER M. A. and GEARING A. J. H. (1992): Marcophage - inflamatory protein protects multipotent hematopoietic cells from the cytotocic effect of hydroxyurea in vivo. Blood, 79, 2605-2609.
14. MANDELLI F., ARCESE W. and AVVISATI G. (1994): The interferons in haematological malignancies. Baillieres Clin. Haematol., 7, 91-113.
15. MOORE M. A. S. (1995): Hematopoietic reconstruction: new approaches. Clin. Cancer Res., 1, 3-9.
16. NEGRIN N. S., KRANTZ S. and GREENBERG P. L. (1993): Treatment of myelodysplastic syndrome using recombinant human granulocyte colony stimulating factor in combination with erythropoietin. Blood, 82, 737-743.
17. OPALKA B., WANDL U. B., RECHER R., KLOKE O., NAGEL- -HIEMKE M., MORITZ T., BERR U., SEEBER S. and NIEDERLE N. (1991): Minimal residual disease in patients with chronic myleogenous leukemia undergoing long-term treatment with recombinant interferon-α2b alone or in combination with interferon γ. Blood, 78, 2188-2193.
18. OSTER W. and SCHULZ G. (1991): Interleukin 3: biological and clinical effects. Int. J. Cell Cloning, 9, 5-23.
19. ROBAK T. (1995): Biologia i farmakologia cytokin. Wydawnictwo Naukowe PWN. Warszawa-Łódź, 1-290.
20. ROBAK T. and KORYCKA A. (1995): The comparison of influence of 2-chIoro-deoxyadenosme (2-CdA) in combination with interferon α (IFN-α) or interferon γ (IFN-γ) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic blasts (CFU-L) in cultures in vitro. Leuk. Lymphoma (in press).
21. ROBAK T., KORYCKA A. and GÓRA-TYBOR J. (1994): The interaction of 2-chloro-deoxyadenosine (2-CdA) and interferon α on normal and myleoid leukemia hematopoiesis in vitro. Leuk. Res., 18, 275-281.
22. ROBAK T, KORYCKA A., GÓRA-TYBOR J., PIOTROWSKA-WRZESIEŃ A. and KRYKOWSKI E. (1992): The influence of recombinant human tumor necrosis factor (rh-TNF-α) on granulocyte-macrophage progenitor cells (CFU-GM) and clonogenic leukaemic blasts (CFU-L) in cultures in vitro. Arch. Immunol. Ther Exp., 40, 339-343.
23. ROBAK T., KORYCKA A. and SZYMAŃSKA B. (1995): The influence of recombinant human tumor necrosis factor and its muteins on normal and leukemic myeloid progenitor cells in cultures in vitro. Exp. Hematol., 23, 884.
24. ROBAK T., KRYKOWSKI E. and WARZOCHA K. (1992): Effects of recombinant human granulocyte-macrophage colony stimulating factor on chemotherapy induced myelosuppression. Arch. Immunol. Ther. Exp., 40, 331-337.
25. ROBAK T., KRYKOWSKI E. and WARZOCHA K. (1994): Treatment of chemotherapy induced or idiopathic bone marrow aplasia with granulocyte colony-stimulating factor (G-CFS). Arch. Immunol. Ther. Exp., 42, 433-438.
26. SCHICK R. P. (1994): Hope for treatment of thrombocytopenia. N. Engl. J. Med., 331, 875-876.
27. SKOTNICKI A. B. (1993): Interferon. Lecznicze zastosowanie w onkohematologii. Wyd. Fundacja Profilaktyki i Leczenia Chorób Krwi, Kraków, 1-258.
28. SMITH II J. W., LONGO D. L., ALWORD W. G., JANIK J. E., SHARFMAN W. H., GAUSE B. L., CURTI B. D., CREEKMORE S. P., HOLMUND J. T., FENTON R. G., SZNOL M., MILLER L. L., SHIMIZU M., OPPENHEIM J. J., FIEM S. J., HURSEY J. C., POWERS G. C. and URBA W. J. (1993): The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin. N. Engl. J. Med., 328, 756-761.
29. SPRIKKELMAN A., DE WOLF Th. M. and VELLENGA E. (1994): The application of hematopoictic growth factor in drug-induced agranulocytosis. A review of 70 cases. Leukemia, 8, 2031-2036.
30. STAHEL R. A., DOST I. M., CERNY T., PICHERT G., HONEGGER H., TOBLER A., JACKY E., FEY M. and PLATZER E. (1994): Randomized study of recombinant human granulocyte-colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplatation. J. Clin. Oncol., 12, 1931-1938.
31. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994): Interferon alpha-2 as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med., 330, 820-825.
32. WARZOCHA K., GÓRA-TYBOR J., KWINKOWSKI M., SZYMAŃSKA B. and ROBAK T. (1994): A comparison of the antileukaemic effects of recombinant human tumor necrosis factor-α and its muteins on leukaemia L1210 and leukaemia P388 in mice. Mediators Inflamm, 3, 411-414.
33. WARZOCHA K., ROBAK T., KORYCKA A., GRACZYK J., PAKULSKA D., GAŁAZKA G and KŁYSIK J. (1992): The influence of recombinant human tumor necrosis factor alpha, singly and in combination with cyclophosphamide or methotrexate on leukemia L1210 and normal hematopoiesis in mice. Arch. Immunol. Ther. Exp., 39, 587-595.